Mycophenolate therapy for kidney transplant patients with no DQ mismatch
Part of Kidney & urinary clinical trials.
This trial tests a mycophenolate-based therapy for kidney transplant recipients who have no HLA-DQ mismatch. If you had your first kidney transplant 3-12 months ago without DQ mismatch and are on standard immunosuppressants, you may qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and have received a first kidney transplant 3-12 months ago
- Have no HLA-DQ mismatch between donor and recipient
- Currently take tacrolimus or cyclosporine, mycophenolate, and steroids
- Have good kidney function (eGFR at least 20)
- No recent signs of rejection or harmful antibodies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study tests whether some older adults who have had a kidney transplant for more than a year can safely stop taking one of their anti-rejection medicines (mycophenolate mofetil, or MMF) instead of staying on it long-term. If you qualify, you may be able to reduce your daily pill burden while keeping your new kidney safe.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.